Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602414 | 1.00 | IRAK4 (0.37) | IRAK4HRH3BRD4ATAD2CHRM2 | |
| SCHEMBL600182 | 0.88 | IRAK4 (0.39) | IRAK4HRH3BRD4ATAD2CHRM2 | |
| SCHEMBL600181 | 0.88 | IRAK4 (0.39) | IRAK4HRH3BRD4ATAD2CHRM2 | |
| SCHEMBL602118 | 0.88 | IRAK4 (0.39) | IRAK4HRH3BRD4ATAD2CHRM2 | |
| SCHEMBL14944080 | 0.87 | IRAK4 (0.37) | IRAK4HRH3BRD4ATAD2CHRM2 | |
| SCHEMBL600635 | 0.86 | IRAK4 (0.37) | IRAK4HRH3BRD4ATAD2CHRM2 | |
| SCHEMBL600636 | 0.86 | IRAK4 (0.37) | IRAK4HRH3BRD4ATAD2CHRM2 | |
| SCHEMBL602758 | 0.83 | CHRM1 (0.38) | IRAK4BRD4ATAD2CHRM2CHRM4 | |
| SCHEMBL603227 | 0.83 | CHRM1 (0.38) | IRAK4BRD4ATAD2CHRM2CHRM4 | |
| SCHEMBL602759 | 0.83 | CHRM1 (0.38) | IRAK4BRD4ATAD2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996188-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-06 | — | — | US | disclosed |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-06 | — | — | US | disclosed |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-06 | — | — | US | disclosed |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
| WO-2007107566-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | IRAK4 1097/4885HRH3 217/4885BRD4 407/4885 |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | IRAK4 1097/4885HRH3 152/4885BRD4 499/4885 |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | IRAK4 2634/4885HRH3 355/4885BRD4 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.